Tenet Healthcare Corporation (BMV:THC)
Mexico · Delayed Price · Currency is MXN | Market Cap | 266.10B -4.1% |
| Revenue (ttm) | 386.78B +4.5% |
| Net Income | 30.70B +17.0% |
| EPS | 345.03 +26.8% |
| Shares Out | n/a |
| PE Ratio | 8.67 |
| Forward PE | 10.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491 |
| Average Volume | 213 |
| Open | 3,550.22 |
| Previous Close | 3,665.00 |
| Day's Range | 3,545.22 - 3,550.22 |
| 52-Week Range | 2,547.79 - 3,995.00 |
| Beta | n/a |
| RSI | 64.00 |
| Earnings Date | Apr 30, 2026 |
About Tenet Healthcare
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial numbers in USD Financial StatementsNews
Tenet Healthcare Transcript: Bank of America Global Healthcare Conference 2026
Q1 volumes improved sequentially, supporting a strong outlook and confidence in annual guidance. Growth strategies focus on high acuity services, ambulatory expansion, and operational efficiency through AI. Capital deployment prioritizes M&A and share repurchases, with a strong cash position maintained.
Tenet to Participate in the BofA Securities Health Care Conference
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the BofA Securities Health Care Conference on Wednesday, May 13, 2026.
Tenet Healthcare price target lowered to $210 from $245 at Baird
Baird lowered the firm’s price target on Tenet Healthcare (THC) to $210 from $245 and keeps a Neutral rating on the shares. The firm updated its model ahead of Q3…
Tenet Healthcare price target lowered to $238 from $257 at Barclays
Barclays analyst Andrew Mok lowered the firm’s price target on Tenet Healthcare (THC) to $238 from $257 and keeps an Overweight rating on the shares post the Q1 report. The…
Tenet Healthcare price target lowered to $260 from $275 at Stephens
Stephens analyst Scott Fidel lowered the firm’s price target on Tenet Healthcare (THC) to $260 from $275 and keeps an Overweight rating on the shares. The firm adjusted estimates following…
Tenet Healthcare price target lowered to $254 from $260 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Tenet Healthcare (THC) to $254 from $260 and keeps an Overweight rating on the shares. Tenet’s consistent execution was on display on…
Tenet Healthcare selloff overdone, compelling longer term, says Cantor
Tenet Healthcare’s (THC) long-term growth story remains intact after Q1, with a clean EBITDA beat and no meaningful change to the underlying narrative despite an in-line print, as near-term noise…
Tenet Healthcare price target lowered to $225 from $250 at KeyBanc
KeyBanc lowered the firm’s price target on Tenet Healthcare (THC) to $225 from $250 and keeps an Overweight rating on the shares. The firm notes Q1 results were solid, highlighted…
Tenet Healthcare price target lowered to $252 from $283 at Guggenheim
Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $252 from $283 and keeps a Buy rating on the shares. Q1 EBITDA upside “layers another proof-point that THC…
Tenet Healthcare Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues of $5.4B and adjusted EBITDA of $1.16B, both above expectations, driven by strong cost management and high-acuity growth. Guidance for 2026 is reaffirmed, with robust cash flow and continued capital deployment for M&A and share repurchases.
Tenet Healthcare Earnings release: Q1 2026
Tenet Healthcare released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Tenet Healthcare Slides: Q1 2026
Tenet Healthcare has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Tenet Healthcare Quarterly report: Q1 2026
Tenet Healthcare has published its Q1 2026 quarterly earnings report on April 30, 2026.
Tenet Healthcare reports Q1 adjusted EPS $4.82, consensus $4.17
Reports Q1 revenue $5.37B, consensus $5.4B. “We delivered strong results in both the Ambulatory and Hospital segments in the first quarter of 2026, characterized by disciplined operations and strong f...
Tenet Healthcare backs FY26 adjusted EBITDA view $4.485B-$4.785B
06:50 EDT Tenet Healthcare (THC) backs FY26 adjusted EBITDA view $4.485B-$4.785B
Tenet Healthcare sees FY26 adjusted EPS $16.38-$18.68, consensus $17.19
Sees FY26 revenue $21.5B-$22.3B, consensus $22.02B.
Tenet Reports Strong First Quarter 2026 Results
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended March 31, 2026. "We delivered strong results in both the Ambulatory and Hosp...
Tenet Healthcare Proxy statement: Proxy filing
Tenet Healthcare filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Tenet Healthcare Proxy statement: Proxy filing
Tenet Healthcare filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
3 Oversold Healthcare Stocks to Buy After Jobs Data
The March jobs report released on April 3 showed an impressive 178,000 jobs were created. Of that number, 76,000 were in the healthcare sector.
Tenet to Report its First Quarter 2026 Results on April 30th
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its first quarter 2026 results before the market opens on Thursday, April 30, 2026, to be followed by a conference call a...
Tenet Healthcare price target raised to $283 from $271 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $283 from $271 and keeps a Buy rating on the shares. Despite Tenet’s roughly 90% return over the past…
Tenet Healthcare price target raised to $265 from $235 at Mizuho
Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $265 from $235 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Unusually active option classes on open March 11th
Unusual total active option classes on open include: Tenet (THC), Shoals Technologies Group (SHLS), Serve Robotics Inc (SERV), AXT (AXTI), Kosmos (KOS), PureFunds Junior Silver Small Cap (SILJ), Enovi...
Tenet Healthcare Transcript: Barclays 28th Annual Global Healthcare Conference
Strong demand for high-acuity care and disciplined capital deployment support robust growth projections. AI and automation drive efficiency, while commercial rates remain favorable and ambulatory expansion continues. Capital priorities include service line investment, share buybacks, and debt reduction.